Author Archives for Adeline Chauvigné

Responsible innovation should supersede the precautionary approach

Interview with Franck Zal, the founder of Hemarina, Vice-president of Atlanpole Biotherapies President of a biotech firm that develops “oxygen... View Article

Rédigé par Adeline Chauvigné, le 2021-06-09

Responsible innovation should supersede the precautionary approach

Interview with Franck Zal, the founder of Hemarina, Vice-president of Atlanpole Biotherapies President of a biotech firm that develops “oxygen... View Article

New member | Amossys

Audit, consulting, evaluation of security products,  training, incident response, R&D… In order to help our customer secure their digital environment,... View Article

Rédigé par Adeline Chauvigné, le 2021-05-31

New member | Amossys

Audit, consulting, evaluation of security products,  training, incident response, R&D… In order to help our customer secure their digital environment,... View Article

New member | NeuroKyma

PROVIDER OF ADVANCED TECHNOLOGY FOR PREDICTIVE ANALYSIS ON CNS TRIALS DISEASES AT THE CROSSING OF E-HEALTH AND NEURO-IMAGING Our mission is... View Article

Rédigé par Adeline Chauvigné, le 2021-05-31

New member | NeuroKyma

PROVIDER OF ADVANCED TECHNOLOGY FOR PREDICTIVE ANALYSIS ON CNS TRIALS DISEASES AT THE CROSSING OF E-HEALTH AND NEURO-IMAGING Our mission is... View Article

XENOTHERA signs a pre-order contract of its anti-COVID treatment with the French government

XENOTHERA announces the signature of a contract to reserve 30,000 unit doses of XAV-19 with the French Ministry of Health... View Article

Rédigé par Adeline Chauvigné, le 2021-05-28

XENOTHERA signs a pre-order contract of its anti-COVID treatment with the French government

XENOTHERA announces the signature of a contract to reserve 30,000 unit doses of XAV-19 with the French Ministry of Health... View Article

GlioCure expands its know-how and technological offer to nanovectors

GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the launch of Cure’nCaps Solutions (www.curencaps.com), a platfom for the formulation... View Article

Rédigé par Adeline Chauvigné, le 2021-06-02

GlioCure expands its know-how and technological offer to nanovectors

GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the launch of Cure’nCaps Solutions (www.curencaps.com), a platfom for the formulation... View Article

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article

Rédigé par Adeline Chauvigné, le 2021-05-26

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article

Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

Rédigé par Adeline Chauvigné, le 2021-05-25

Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

New member | Attonuclei

ATTONUCLEI took advantage of its 10 years of experience in functionalized Quantum Dots our company is a high-tech company whose... View Article

Rédigé par Adeline Chauvigné, le 2021-06-02

New member | Attonuclei

ATTONUCLEI took advantage of its 10 years of experience in functionalized Quantum Dots our company is a high-tech company whose... View Article

OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multiepitopes. CoVepiT epitopes* are selected from 11... View Article

Rédigé par Adeline Chauvigné, le 2021-05-26

OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multiepitopes. CoVepiT epitopes* are selected from 11... View Article

Valneva Announces Closing of $107.6 million Global Offering

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

Rédigé par Adeline Chauvigné, le 2021-05-11

Valneva Announces Closing of $107.6 million Global Offering

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article